Centocor Research & Development, Inc.
4 clinical trials · Sponsor
◉ Watch Centocor Research & Development, Inc.
| Record | Firm | Date |
|---|---|---|
| A Study of the Safety and Efficacy of Single-agent Carlumab (an Anti-Chemokine Ligand 2 [CCL2]) in Participants With Metastatic Castrate-Resistant Prostate Cancer (NCT00992186) | Centocor Research & Development, Inc. | 2009-09-01 |
| A Study of the Safety and Pharmacokinetics of CNTO 136 in Patients With Cutaneous Lupus Erythematosus and Systemic Lupus Erythematosus (NCT01702740) | Centocor Research & Development, Inc. | 2007-03-01 |
| A Study of Safety and Effectiveness of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Plaque-type Psoriasis (NCT00267969) | Centocor Research & Development, Inc. | 2005-12-01 |
| A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis (NCT00307437) | Centocor Research & Development, Inc. | 2005-05-01 |
Track Centocor Research & Development, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.